華熙生物(688363.SH)上半年淨利潤預增30%-40%
格隆匯7月1日丨華熙生物(688363.SH)公佈,預計2021年上半年實現營業收入為人民幣184720萬元至194192萬元,與上年同期(法定披露數據)相比,將增加人民幣89992萬元到99464萬元,同比增加95%到105%。
歸屬於母公司所有者的淨利潤為人民幣34718萬元至37388萬元,與上年同期(法定披露數據)相比,將增加人民幣8012萬元到10682萬元,同比增加30%到40%。
歸屬於母公司所有者的扣除非經常性損益的淨利潤為人民幣29279萬元至32792萬元,與上年同期(法定披露數據)相比,將增加5856萬元到9369萬元,同比增加25%到40%。
公司2021年上半年業績較上年同期增長的主要原因為:1)隨着疫情影響的逐漸好轉,公司各業務板塊收入均實現一定的增長,其中公司原料業務以及醫療終端業務穩步增長,功能性護膚品業務板塊收入在2021年上半年延續高增長態勢,取得大幅增長,公司營業收入實現95%-105%的增長。
2)營業收入增加的同時,由於公司重視底層科技支撐,研發投入持續增長。同時,公司各項業務仍處於戰略發展機遇期,品牌建設、組織升級、新業務佈局等戰略性投入也有所增加,歸屬於母公司所有者的淨利潤實現30%-40%的增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.